

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

1641  
PTO/SB/21 (05-03)Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/080,273	
	Filing Date	February 19, 2002	
	First Named Inventor	Lu, Peter S.	
	Art Unit	1641	
	Examiner Name		
Total Number of Pages in This Submission		Attorney Docket Number	020054-002310US

TECH CENTER 1600-1900  
AUG 25 2003  
RECEIVED

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of fifty-two (52) cited references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Ausenhus Reg. No. 42,271
Signature	
Date	08-20-03

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Nicole M. Burke		
Signature		Date	8-20-2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT  
Attorney Docket No.: 020054-002310US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On 08-20-2003

TOWNSEND and TOWNSEND and CREW LLP

By: *Nicole Burke*  
Nicole Burke



RECEIVED  
AUG 25 2003  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Lu et al.

Application No.: 10/080,273

Filed: February 19, 2002

For: PDZ DOMAIN INTERACTIONS  
AND LIPID RAFTS

Examiner:

Art Unit: 1641

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Scott Ausenhuss", written over the typed name.

Scott L. Ausenhuss  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
47111933 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO/SB/08A

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 4

Complete if Known

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1641
Examiner Name	
Attorney Docket Number	020054-002310US

RECEIVED  
AUG 25 2003  
TECH CENTER 1601/2900

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-5,632,994	05/27/97	Reed et al.	
	A2	US-5,747,245	05/05/98	Reed et al.	
	A3	US-5,876,939	03/02/99	Reed et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	PCT	WO 98/05347	A1	02-12-1998			<input type="checkbox"/>
	B2	PCT	WO 98/23781	A1	06-04-1998			<input type="checkbox"/>
	B3	PCT	WO 98/40407	A1	09-17-1998			<input type="checkbox"/>
	B4	PCT	WO 99/03974	A1	01-28-1999			<input type="checkbox"/>
	B5	PCT	WO 99/07846	A1	02-18-1999			<input type="checkbox"/>
	B6	PCT	WO 00/15794	A1	03-23-2000			<input type="checkbox"/>
	B7	PCT	WO 00/31124	A2	06-02-2000			<input type="checkbox"/>
	B8	PCT	WO 00/48002	A1	08-17-2000			<input type="checkbox"/>
	B9	PCT	WO 00/69897	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>
	B10	PCT	WO 00/69898	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>

Examiner  
Signature


Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1749/PT

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 2 of 4

### Complete if Known

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1641
Examiner Name	
Attorney Docket Number	020054-002310US

TECH CENTER 1601/2600  
AUG 25 2003

RECEIVED

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Altin, J. and Sloan, E. "The role of CD45 and CD45-associated molecules in T cell activation" <i>Immunology and Cell Biology</i> , 1997, pp. 430-445, Vol. 75.	
	C2	Bals, R. et al. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide", <i>Infection and Immunity</i> , November 1999, pp. 6084-6089, Vol. 67, No. 11.	
	C3	Barclay, A., et al., "The Leucocyte Antigen Factsbook", <i>Harcourt Braces &amp; Company</i> , page 363, (1997).	
	C4	Bruyns, E. et al. "Identification of the Sites of Interaction between Lymphocyte Phosphatase-associated Phosphoprotein (LPAP) and CD45", <i>Journal of Biological Chemistry</i> , December 29, 1996, pp. 31372-31376, Vol. 270, No. 52, U.S.A.	
	C5	Cherukuri, A. et al. "Floating the raft hypothesis: lipid rafts play a role in immune cell activation", <i>Immunity</i> , June 2001, pp.657-660, Vol. 14, Cell Press.	
	C6	Ding, I. Et al., "Biochemical and Functional Analysis of Mice Deficient in Expression of the CD45-Associated Phosphoprotein LPAP", <i>European Journal of Immunology</i> , 29(12):3956-61 (1999).	
	C7	Doyle, D. A., et al., "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ", <i>Cell</i> , 85(7):1067-76, (1996).	
	C8	Faulkner, G. et al. "A New Z-band Alternatively Spliced PDZ-motif Protein." <i>The Journal of Cell Biology</i> , July 26, 1999; pp. 465-475, Vol. 146, No. 2.	
	C9	Gardioli, D. et al. "Oncogenic human papillomavirus E6 proteins target the discs large tumor suppressor for proteasome-mediated degradation", <i>Oncogene</i> , 18(40):5487-5496, (1999).	
	C10	Gee, S.H. et al., "Interaction of Muscle and Brain Sodium Channels with Multiple Members of the Syntrophin Family of Dystrophin-Associated Proteins", <i>J. Neuroscience</i> , 18(1):128-137, (1998).	
	C11	Gee, S.H., et al., "Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains", <i>The Journal of Biological Chemistry</i> , 273(34):21980-21987, (1998).	
	C12	Hanada, T., et al., "Human Homologue of the Drosophila Discs Large Tumor Suppressor Binds to p56 <sup>lck</sup> Tyrosine Kinase and Shaker Type Kv1.3 Potassium Channel in T. Lymphocytes", <i>The Journal of Biological Chemistry</i> , 272(43):26899-26904, (1997).	
	C13	Kiyono, T. et al. "Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein", <i>Proc. Natl. Acad. Sci.</i> , October 1997, pp. 11612-11616, Vol. 94, U.S.A.	


Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449-PROTEMA

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of 4

**Complete if Known**

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1641
Examiner Name	
Attorney Docket Number	020054-002310US

TECH CENTER 16002500  
AUG 23 2003

RECEIVED

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C14	Kobayashi, I., et al., "Identification of an Autoimmune Enteropathy-related 75-kilodalton Antigen", <i>Gastroenterology</i> , October 1999, pp. 823-830, Vol. 117, No. 4.	
	C15	Maekawa, K., et al., "Association of Protein-Tyrosine Phosphatase PTP-BAS with the Transcription-factor-inhibitory Protein IκBα Through Interaction Between the PDZ1 Domain and Ankyrin Repeats", <i>Biochemical Journal</i> , 337(2):179-187, (1999).	
	C16	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain", <i>DNA Research</i> , 1996, pp. 321-329, Vol. 3.	
	C17	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain (Supplement)", <i>DNA Research</i> , 1996, pp. 341-354, Vol. 3, Supplement.	
	C18	Nishihara, H. et al. "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins", <i>Biochimica et Biophysica Acta</i> , 1999, pp. 179-187, Elsevier Publishing.	
	C19	Nishihara, H. "Analysis of Hematopoietic Cell Specific Protein, M-DOCK", <i>Hokkaido Igaku Zasshi</i> , March 1999, p. 157-166, Vol. 74, No. 2.	
	C20	Patel, V. et al., "A Molecular Framework for 2-Step T Cell Signaling: Lck Src Homology 3 Mutations Discriminate Distinctly Regulated Lipid Raft Reorganization Events", <i>Journal of Immunology</i> , 166(2):754-64 (2001).	
	C21	Reynaud, C. et al., "The PDZ Protein TIP-1 Interacts with the Rho Effector Rhotekin and Is Involved in Rho Signaling to the Serum Response Element", <i>The Journal of Biological Chemistry</i> , 275(43):33962-33968, (2000).	
	C22	Rousset, R., et al., "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins" <i>Oncogene</i> , 16(5):643-54, (1998).	
	C23	Saras, J., et al., "PDZ Domains Bind Carboxy-Terminal Sequences of Target Proteins", <i>Trends in Biochemical Sciences</i> , en, Elsevier Publication, Cambridge, 21(12):455-458, (1996).	
	C24	Schepens, J., et al., "The Neuronal Nitric Oxide Synthase PDZ Motif Binds to -G(D.E)XV Carboxy Terminal Sequences", <i>Febs Letters</i> , 409(1-2):53-56, (1997).	
	C25	Shibuya, A., et al., "DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes", <i>Immunity</i> , 4:573-581, (1996).	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449 (Rev. 11/99)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 4 of 4

**Complete if Known**

Application Number	10/080,273
Filing Date	February 19, 2002
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1641
Examiner Name	
Attorney Docket Number	020054-002310US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C26	Shibuya, A., et al., "Protein Kinase C is Involved in the Regulation of Both Signaling and Adhesion Mediated by DNAX Accessory Molecule-1 Receptor", <i>The Journal of Immunology</i> , 161:1671-1676, (1998).	
	C27	Shibuya, K., et al., "Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule", <i>Immunity</i> , 11:615-623, (1999).	
	C28	Suzuki, T., et al., "Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control", <i>Oncogene</i> , 18(44):5967-72, (1999).	
	C29	Vallénus, T. et al. "CLP-36 PDZ-LIM Protein Associates with Nonmuscle alpha-Actinin-1 and alpha-Actinin-4." <i>The Journal of Biological Chemistry</i> , April 14, 2000; pp. 11100-11105, Vol. 275, No. 15.	
	C30	Wechsler, A. et al. "Brain Spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin." <i>The EMBO Journal</i> , 1998, pp. 3931-3939, Vol. 17, No. 14.	
	C31	Xia, H. et al. "Actinin-associated LIM Protein: Identification of a Domain Interaction between PDZ and Spectrin-like Repeat Motifs", <i>The Journal of Cell Biology</i> , October 1997, pp. 507-515, Vol. 139, No. 2.	
	C32	Yanagisawa, J., et al., "The Molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis", <i>J. Biol. Chem.</i> , 272(13):8539-8545, (1997).	
	C33	GenBank, Accession Number BM845132, 03/06/2002	
	C34	GenBank, Accession Number CB131761, 01/29/2003	
	C35	GenBank, Accession Number CB961389, 04/28/2003	
	C36	GenBank, Accession Number CB995033, 04/30/2003	
	C37	Genbank, Accession Number D86964, 02/07/1999	
	C38	OMIM Database entry entitled, '147138 Fc Fragment of IgE, High Affinity I, Receptor for, Beta Subunit; FCER1B', www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmmim?147138, 08/27/1992 Victor A. McKusick.	
	C39	OMIM Database entry entitled, "603122 Dedicator of Cytokinesis 2; Dock 2" www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmmim?603122, 10/12/1998 Rebekah S. Rasooly.	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.